A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of GS-9876 in Subjects with Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 26 May 2017
At a glance
- Drugs GS 9876 (Primary)
- Indications Autoimmune disorders; Rheumatoid arthritis; Sjogren's syndrome
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 18 May 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 18 May 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
- 13 Dec 2016 Status changed from not yet recruiting to recruiting.